Navigation Links
MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology
Date:2/28/2011

lopment.  In the clinical trial, patients administered LEVADEX themselves using the proprietary TEMPO® inhaler.  LEVADEX contains a novel formulation of dihydroergotamine (DHE).  LEVADEX was evaluated in the efficacy portion of FREEDOM-301, MAP Pharmaceuticals' Phase 3 pivotal trial, which included 395 patients in the LEVADEX arm and 397 patients in the placebo arm.  In the Phase 3 trial, patients taking LEVADEX therapy had statistically significant improvement at two hours compared to patients on placebo for all four co-primary endpoints:

  • Pain relief: 58.7 percent of patients who received LEVADEX compared with 34.5 percent for placebo (p<0.0001);
  • Phonophobia free: 52.9 percent of patients who received LEVADEX compared with 33.8 percent for placebo (p<0.0001);
  • Photophobia free: 46.6 percent of patients who received LEVADEX compared with 27.2 percent for placebo (p<0.0001); and
  • Nausea free: 67.1 percent of patients who received LEVADEX compared with 58.7 percent for placebo (p=0.02).

  • The most common adverse event reported was medication aftertaste at six percent versus two percent for placebo. The next most common adverse event was nausea at five percent compared with two percent for placebo.  There were no decreases in lung function, as measured by spirometry, between the active and placebo groups. 

    About Migraine Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound).  According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days.  On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly.  The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migr
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
    2. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
    3. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
    4. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
    5. UCLA and Sound Pharmaceuticals Identify a Key Hearing Regeneration Protein in the Human Inner Ear
    6. JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
    7. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
    8. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
    9. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
    10. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
    11. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... Sept. 23, 2014 The Pennsylvania State Police will ... 27, as part of National Prescription Drug Take-Back Day. ... Take-Back Day is a national initiative, conducted ... aimed at encouraging the public to dispose of expired, ... abuse and theft. From 10 a.m. to ...
    (Date:9/23/2014)... Canada , September 23, 2014 ... and lifestyle related disorders and increasing number of foreign ... demand for probiotic in India ... as one of the most high growth potential markets ... concerns among consumers especially among the youth, changing food ...
    (Date:9/23/2014)... 23, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... (NOL) from Health Canada to begin clinical trials ... lead product candidate KP201 (benzhydrocodone hydrochloride and acetaminophen).  ... acute moderate to moderately severe pain. The Health ...
    Breaking Medicine Technology:India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
    ... , MOUNTAIN VIEW, Calif. , Feb. 16 ... it will host an investor/analyst meeting on Thursday, February 18, 2010 ... New York City . , The meeting will include presentations from: , ... James Cassella , PhD - SVP, Research and Development, ...
    ... , LAWRENCEVILLE, N.J. , Feb. 16 ... announced today that Wayne S. Mulcahy , Ph.D., ... A wholly owned subsidiary of Princeton Pharma Holdings LLC, ... unique products in ophthalmology and orphan diseases. , ...
    Cached Medicine Technology:Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010 2Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010 3Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010 4Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations 2
    (Date:9/23/2014)... 23, 2014 Florida Hospital Zephyrhills ... renovated Women’s Health Center on Wednesday, September 24. ... the specially designed center offers a new level ... County. The Women’s Health Center offers comprehensive women’s ... labor and delivery through The Baby Place®, and ...
    (Date:9/23/2014)... published studies found that FDG-PET technology is less ... in regions where infections like histoplasmosis or tuberculosis ... for cancer could lead to unnecessary tests and ... mortality. , Histoplasmosis and other fungal diseases ... in bird droppings and are found in soils. ...
    (Date:9/23/2014)... Sinica, the preeminent academic institution in the Republic ... agreement to develop a unique educational and scientific ... to translate innovative technologies and commercially relevant discoveries ... Sept.12 in Taipei by Harris Lewin, vice chancellor ... Wong of Academia Sinica. The program will be ...
    (Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows all about ... can be treated. , A medically retired Army veteran, ... platoon sustained multiple attacks resulting in five casualties. After ... PTSD and honorably discharged from the Army. , “I ... myself from my friends and family,” recalled O’Farrell, who ...
    (Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
    Breaking Medicine News(10 mins):Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Consumer Health Reports Debuts Revolutionary Review Website 2
    ... in those who also have heart disease , TUESDAY, Aug. ... prostate cancer and who also have underlying heart disease may ... In fact, such hormone therapy may actually increase their odds ... attack or heart failure, use of hormone therapy for prostate ...
    ... ... Health System to stable, citing the health system,s "improving financial metrics" and "better-than-expected ... ... its outlook for Wellmont Health System to stable, citing the health system,s ...
    ... , SAN DIEGO, Aug. 25 CareFusion ... 500 index following the company,s planned spinoff from Cardinal Health on Aug. ... 1, coinciding with its first day of regular-way trading on the New ... "Our inclusion in the S&P 500 is a testament to our ...
    ... , , , ... the ideal time to honor the life of a beloved pet--yours or someone ... lost pet and also offer animal lovers an opportunity to improve the future ... are customized with the names of the pet owner and the pet ...
    ... the anti-cancer drug, experts say , TUESDAY, Aug. 25 (HealthDay ... lower the chances of developing the most common type of ... raises the risk of getting a more aggressive cancer in ... the finding is no reason to ditch the anti-cancer drug, ...
    ... , IRVINE, Calif., Aug. 25 Masimo ... and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that ... Report as one of ,America,s Best Children,s Hospitals, has completed ... , , Masimo SET has been clinically ...
    Cached Medicine News:Health News:Hormone Therapy for Early Prostate Cancer Not Always Best 2Health News:Hormone Therapy for Early Prostate Cancer Not Always Best 3Health News:Standard & Poor's Upgrades Wellmont Outlook 2Health News:Standard & Poor's Upgrades Wellmont Outlook 3Health News:CareFusion Corp to be Included in S&P 500 Index 2Health News:Honor Spirit and Memory of a Special Pet During National Pet Memorial Month 2Health News:Tamoxifen May Up Risk of Second, More Aggressive Breast Cancer 2Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 2Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 3Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 4Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 5
    The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
    Microforceps : Asymmetrical Endgripping Forceps...
    Pic forceps design that is slightly curved; tips have special "surface treatment" for enhanced manipulation of the retina....
    Microforceps : Eckardt Endgripping Forceps...
    Medicine Products: